Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan Greater China, started with the broader internet + healthcare market and shared the industry-wide landscape and development trends of digital health.
He pointed out that digitization is becoming a major trend in the healthcare sector, helping to address pain points such as the over-reliance on drug sales, uneven distribution of medical resources, and inverted demand in China's previous healthcare service system. As an emerging industry, digital big health holds tremendous market potential in China.Currently, a large number of participants are focusing on different directions in the digital big health market, actively exploring various business models. 'Pharmaceutical companies are placing increasing emphasis on digital strategies, strengthening their capabilities through the construction of online channels such as brand marketing, remote services, medical e-commerce, and disease management. The importance of digital health infrastructure services is also becoming increasingly prominent. Driven by policies, hospitals at all levels are actively building internet hospitals, realizing internet + off-site extensions, and accelerating the basic construction of digital healthcare.'He believes that driven by technological innovation, frequent favorable policies, and the improvement of residents' health awareness, the digital big health industry is expected to enter a new development period.
As a globally renowned growth consulting firm, Frost & Sullivan integrates nearly 60 years of consulting experience from around the world. Over the past 23 years, it has dedicated itself to serving the booming Chinese market and has made the healthcare industry one of its core research areas. The Frost & Sullivan healthcare team possesses strong capabilities and rich experience in the field of life sciences. It has extensive medical enterprise clients in China and has established a vast customer network and patent database over the past 20 years, covering sales information on innovative drugs in China and financial information from multiple manufacturers. It has established good or deep cooperative relationships with experts across the entire industrial chain, ranging from KOLs to industry experts and government officials.
Frost & Sullivan has a team of senior technical consultants, many of whom have decades of clinical development experience in innovative drugs and medical devices both within and outside the enterprise sector. Over the past sixteen years, the Frost & Sullivan healthcare team has provided financing financial advisory, IPO industry advisory, technical advisory, strategic advisory, management advisory, and other services to hundreds of outstanding domestic and international biopharmaceuticals, medical devices, healthcare services, and internet healthcare companies. It is a leader and witness to the development of China's pharmaceutical industry. In terms of the number of filings, the Frost & Sullivan healthcare team maintains an absolute leading position in Hong Kong healthcare IPOs, continuously occupying more than 90% of the market share from 2018 to 2020.
